Ac-SDKP vs Glutathione

Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is an endogenous tetrapeptide generated from the N-terminus of thymosin beta-4 by the enzyme prolyl oligopeptidase, with further regulation by angiotensin-converting enzyme (ACE), and is characterized by roles in hematopoietic progenitor regulation and anti-fibrotic signaling in renal, cardiac, and vascular tissue. Ac-SDKP inhibits collagen synthesis and fibroblast proliferation, reduces TGF-beta-1-mediated fibrotic signaling, and promotes anti-inflammatory macrophage polarization in preclinical models, suggesting a role in tissue homeostasis downstream of the thymosin beta-4 pathway. Preclinical studies in rodent models of renal fibrosis and systemic lupus erythematosus — predominantly from the NIH-funded Rhaleb and Carretero laboratory at Henry Ford Health — have demonstrated that exogenous Ac-SDKP reduces collagen deposition and inflammatory infiltrate; no human clinical trials have been completed or indexed in PubMed. Ac-SDKP has no FDA approval and no approved indication in any jurisdiction; it is studied as a research compound with a plausible anti-fibrotic mechanism and consistent preclinical evidence, but extrapolation of rodent findings to human therapeutic outcomes has not been validated by any clinical investigation.

Master endogenous antioxidant tripeptide; neutralizes ROS, regenerates vitamins C and E, supports phase II liver detoxification, maintains intracellular redox balance

Glutathione (γ-glutamyl-cysteinyl-glycine, GSH) is the most abundant endogenous intracellular antioxidant tripeptide, synthesized from cysteine, glutamate, and glycine in virtually all mammalian cells, where it maintains redox homeostasis by scavenging reactive oxygen species, regenerating oxidized vitamins C and E, and serving as substrate for glutathione peroxidase and glutathione S-transferase detoxification pathways. Cysteine availability is the rate-limiting step in GSH synthesis, and depletion of glutathione is a consistent feature of neurodegenerative conditions including Parkinson's disease substantia nigra, where oxidative stress plays a central role in dopaminergic neuronal injury. A randomized, double-blind pilot trial published in Movement Disorders evaluated intravenous glutathione in Parkinson's disease patients; separately, a pharmacokinetic study established that orally ingested glutathione is not systemically bioavailable — failing to raise plasma or erythrocyte GSH levels — which defines the rationale for parenteral and liposomal delivery formulations. Glutathione is available as a compounded injectable preparation and as an oral dietary supplement, but it has no FDA approval for any clinical indication; IV glutathione is administered off-label in integrative settings with an evidence base insufficient to establish efficacy for any specific condition, and claims regarding its use for general wellness or skin lightening lack rigorous clinical support. IV glutathione therapy: intravenous glutathione is offered at integrative medicine clinics, IV therapy lounges, and some telehealth platforms as part of NAD+ IV drips, wellness protocols, or standalone antioxidant infusions. Common clinical doses studied range from 600 mg to 1,200 mg IV per session. IV administration bypasses the oral bioavailability problem and raises plasma glutathione levels acutely, though the clinical significance of this acute elevation for most wellness endpoints remains unestablished in controlled trials. Glutathione IV drips are frequently paired with NAD+ infusions given overlapping antioxidant and mitochondrial support rationales in integrative clinical practice. Glutathione for skin: glutathione has been studied in clinical settings for its melanin-inhibiting properties — specifically, its ability to shift melanin synthesis from eumelanin (darker) toward phaeomelanin (lighter pigmentation) via tyrosinase pathway inhibition. Several small RCTs from Asian clinical centers have examined IV and oral glutathione for skin lightening, with mixed results; the evidence base is not sufficient for regulatory approval in any jurisdiction, and high-dose IV glutathione for cosmetic pigmentation is controversial from a safety standpoint in medical literature. N-acetylcysteine (NAC) is a glutathione precursor with superior oral bioavailability and its own independent research base; it is often preferred for systemic antioxidant applications. Providers offering IV glutathione as part of wellness protocols are listed in the PeptideBase directory.